


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet



Enantioselective synthesis of condensed and transannular ring skeletons containing pyrrolidine moiety

Fanyang Mo^a, Fei Li^a, Di Qiu^a, Jianbo Wang^{a,b,*}

^aBeijing National Laboratory of Molecular Sciences (BNLMS) and Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry, Peking University, Beijing 100871, China

^bState Key Laboratory of Organometallic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

ARTICLE INFO

Article history:

Received 4 October 2009

Received in revised form 29 November 2009

Accepted 4 December 2009

Available online 26 December 2009

Keywords:

Enantioselective synthesis

Diazo compounds

Nucleophilic addition

Pyrrolidine

Ring-closing olefin metathesis

ABSTRACT


A new approach toward condensed and transannular ring structures containing pyrrolidine unit has been developed, based on diastereoselective nucleophilic addition of lithium enolate of α -diazoacetoacetate to chiral *N*-sulfinyl imine and ring-closing metathesis.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

The enantioselective construction of pyrrolidine skeletons, a frequently observed structural unit in various alkaloid type natural products, pharmaceutical molecules, etc., is of current interest.^{1,2} Among the various pyrrolidine-containing structures, condensed and transannular ring skeletons are important structural subunits present in many alkaloids and are common scaffolds in biologically active and pharmaceutically significant compounds.³ For example, (+)-harmicine was extracted from the Malaysian plant *Kopsia griffithii* by Kam and Sim and showed strong anti-Leishmania activity.⁴ Polyhydroxylated pyrrolizidines and indolizidines (related to iminosugars) such as Swainsonine have increasingly gained attention because of their ability to inhibit glycosidases (Scheme 1).⁵

Besides the classical total synthesis approach to complex structures, particularly attractive is the development of synthetic methodologies that allow for the preparation of a large number of structurally similar analogs from limited few common intermediates.⁶ As a part of our program for the development of novel synthetic methodology based on diazo compounds, we have recently developed a concise and efficient method to construct




Scheme 1.

5-substituted 2-oxo and 3-oxo pyrrolidines with high enantiomeric purity.⁷ Here we report the further application of this methodology to the enantioselective synthesis of condensed and transannular ring skeletons containing pyrrolidine units.

This new approach to condensed and transannular ring skeletons is outlined in Scheme 2. With the reactions that have been reported previously, we can easily prepare 2-oxo-5-vinylpyrrolidine **1**. Introducing the side chains that contain olefin moiety to either *N* or C3 position affords key intermediates **2** and **3**, respectively. Ring-closing metathesis (RCM),⁸ which has emerged as powerful tool to construct ring system through intramolecular C=C bond formation, is applied to **2** and **3** to afford condensed and transannular ring systems **4** and **5**.⁹



* Corresponding author. Fax: +86 10 6275 1708.

E-mail address: wangjb@pku.edu.cn (J. Wang).



1.1. Results and discussions

The investigation began with the preparation of chiral pyrrolidine **10** (Scheme 3). First, diastereoselective addition of lithium enolate of α -diazoacetoacetate **7** to chiral *N*-sulfinyl imine **6** afforded δ -*N*-sulfinylamino α -diazo β -ketoester **8** in 70% yield. HPLC analysis showed compound **8** with 97% de. The absolute configuration of the newly generated chiral center in β -ketoester **8** was established by X-ray analysis of its single crystal.¹⁰ The absolute configuration is also confirmed by converting **8** into known compounds (vide infra). When the chiral center of sulfur has *S* configuration, the newly formed chiral center has *R* configuration. This stereochemical outcome is consistent with the previous reports of the addition of enolates derived from esters or ketones to chiral *N*-sulfinyl imines.^{11,12}




X-ray structure of **8**

Scheme 3.

Our previous study has shown that *N*-sulfinyl group is liable to decompose in the Wolff rearrangement reaction, which is under irradiation conditions. Thus, the *N*-sulfinyl group is replaced by *N*-Boc group in two steps. First, β -ketoester **8** was treated with 5 equiv of TFA in MeOH to remove the *N*-sulfinyl auxiliary, giving the free amine as the trifluoroacetate salt. Being neutralized with 6 equiv of Et₃N, the amine was treated with Boc₂O and catalytic


amount of DMAP, affording *N*-Boc protected diazo compound **9** in 95% yield. Irradiation of diazo compound **9** with high-pressure Hg lamp ($\lambda > 300$ nm) in a Pyrex tube gave (5*R*)-2-oxo-3-allyloxy-carbonyl-5-vinylpyrrolidine **10** in 60% isolated yield.^{7,13}

With **10** in hand, we next proceeded to build the condensed rings based on the strategy summarized in Scheme 2. The condensed alkaloid structure can be built from **10** through *N*-alkylation and ring-closing metathesis. Thus, Pd(PPh₃)₄-catalyzed deallyloxycarbonylation¹⁴ in the presence of morpholine afforded (5*R*)-*N*-Boc-2-oxo-5-vinylpyrrolidine **11** in 88% yield. Removal of the nitrogen protecting group with 5 equiv of TFA in CH₂Cl₂ gave (*R*)-2-oxo-5-vinylpyrrolidine in nearly quantitative yield. (*R*)-2-Oxo-5-vinylpyrrolidine was then reacted with allyl bromide, homoallyl bromide, and pent-4-enyl 4-methylbenzenesulfonate, respectively, in the presence of base to give the products **13**, **14**, and **15** as the precursors for the next RCM reaction. Finally, the pyrrolidines **13**, **14**, and **15** were subjected to the RCM reaction by using second generation Grubbs catalyst. The expected ring-closing products **16**, **17**, and **18** were obtained in nearly quantitative yields (Scheme 4). Products **16**, **17**, and **18** are potentially valuable chiral building blocks for enantioselective synthesis of polysubstituted pyrrolidines and indolizidines.¹⁵




Scheme 4.

Next, we conceived the further application of pyrrolidine **10** in the construction of transannular ring structures. As shown in Scheme 2, by introducing an alkene moiety on C3 of pyrrolidine ring, the transannular ring structures could be built by the same RCM strategy. First, the pyrrolidine **10** was subjected to Pd-catalyzed decarboxylative allylic alkylation, with the expectation that C3 allylation might occur simultaneously. However, the desired intramolecular allylic alkylation process did not occur when **10** was catalyzed by Pd(PPh₃)₄ using THF as solvent (Eq. 1). Changing solvent and Pd catalyst were attempted, but all efforts proved to be fruitless.




We then attempted a different approach, which was direct allylic alkylation of **10** followed by deallyloxycarbonylation. As outlined in Scheme 5, treatment of **10** in acetone with allyl bromide and K_2CO_3 at $60^\circ C$ for 3 h furnished a pair of diastereoisomers **20** in 87% yield, which was subjected to the Pd-catalyzed deallyloxycarbonylation to afford two products **19a** and **19b** in 1:1 ratio. Compounds **19a** and **19b** could be separated with chromatography column and their structure could be assigned by NOE experiments. The cis isomer **19a** was then subjected to RCM reaction with Grubbs second catalyst, affording the ring-closing product (+)-**23** in nearly quantitative yield.



Scheme 5.


Compound (–)-**23** is a key intermediate in the total synthesis of an anti-influenza neuramidase inhibitor Oseltamivir (Tamiflu) reported by Corey and co-workers (Scheme 6).¹⁶



Scheme 6.

With the same approach, [4.2.1] bicyclic system (+)-**24** could be synthesized by easily changing allyl bromide to homoallyl bromide in the alkylation of **10** and then following the same subsequent steps as for the synthesis of (+)-**23**.

Finally, total synthesis of (*R*)-Pyrrolam A¹⁷ has been achieved with this methodology (Scheme 7). RCM precursor (*R*)-**25** was obtained from **12** via simple reduction and acylation with a yield of 60% and then (*R*)-**25** was subjected to RCM reaction catalyzed by 10 mol % of Grubbs second catalyst to give (*R*)-Pyrrolam A **26** in 68% isolated yield.



Scheme 7.

2. Conclusions

In summary, we have developed versatile routes to condensed and transannular ring structures containing pyrrolidine unit. These products may be potential scaffolds for the synthesis of alkaloids of biological and pharmaceutical interests. In addition, (*R*)-Pyrrolam A was synthesized enantioselectively, further exhibiting application flexibility of this methodology. Efforts to apply this chemistry to the synthesis of alkaloids of more structural complexity are underway in our laboratory.

3. Experimental section

3.1. General

Caution: diazo compounds are generally toxic and potentially explosive. They should be handled with care in a well-ventilated fume hood.

3.1.1. (*R*)-Allyl 2-diazo-5-((*S*)-4-methylphenylsulfonamido)-3-oxohept-6-enoate (8**).** To a solution of **6**¹⁸ (193 mg, 1 mmol) in CH_2Cl_2 (25 mL) was added LiHMDS (2 mmol, 1.0 M in hexane) at $-78^\circ C$ and then **7** (252 mg, 1.5 mmol) in CH_2Cl_2 (5 mL) was dropped in the solution in 5 min. After stirring for another 10–15 min, the reaction was quenched with saturated aqueous NH_4Cl at $-78^\circ C$ and then warmed quickly to room temperature. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (2×15 mL). The organic layers were combined and dried over Na_2SO_4 . Then the solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography (petroleum ether/ethyl acetate 3:1) to give the addition products **8** (252 mg, 70% yield). IR (film) 3208, 2137, 1714, 1649, 1371, 1304, 1090, 1057, 1016, 923, 813, 746 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 7.57 (d, $J=7.8$ Hz, 2H), 7.28 (d, $J=7.8$ Hz, 2H), 6.02–5.87 (m, 2H), 5.37–5.21 (m, 4H), 4.82 (d, $J=7.2$ Hz, 1H), 4.70–4.67 (m, 2H), 4.31 (qd, $J=6.1, 7.2$ Hz, 1H), 3.19 (dd, $J=4.5, 16.5$ Hz, 1H), 3.08 (dd, $J=7.1, 16.5$ Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 190.1, 160.6, 141.7, 141.1, 138.1, 131.1, 129.3, 125.4, 119.2, 116.6, 65.8, 53.1, 45.6, 21.2; EIMS (m/z , relative intensity): 361 (4), 243 (3), 222 (25), 194 (9), 171 (7), 155 (7), 139 (100), 123 (17), 108 (16), 91 (58), 77 (13), 65 (23), 41 (100), 27 (16). HRMS (EI) calcd for $C_{17}H_{19}N_3O_4S$ 361.1096, found 361.1095. $[\alpha]_D^{20} +127.0$ (c 0.8, $CHCl_3$).

3.1.2. (*R*)-Allyl 5-(*tert*-butoxycarbonylamino)-2-diazo-3-oxohept-6-enoate (9**).** The addition product **8** (1.083 g, 3 mmol) was treated with TFA (1.710 g, 15 mmol, 5.0 equiv) in MeOH (20 mL) at $0^\circ C$. The reaction was monitored by TLC and the sulfonyl group in **8** was removed in about 2 h to give the corresponding trifluoroacetate salt. The solution was concentrated, and then was dissolved in THF (20 mL). The solution was treated with Boc_2O (770 mg, 3.6 mmol, 1.2 equiv), Et_3N (1.818 g, 18 mmol, 6 equiv) and a catalytic amount of DMAP (18 mg, 0.15 mmol, 0.05 equiv) at $0^\circ C$. After stirred for about 2 h at this temperature, the solution was concentrated and purified by flash chromatography (petroleum ether/ethyl acetate 10:1) to give the *N*-Boc protected diazo product **9** (920 mg, yield 95%) as a yellow oil. IR (film) 3374, 2974, 2135, 1712, 1650, 1366, 1308, 1169, 922, 743 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 6.01–5.81 (m, 2H), 5.39–5.29 (m, 2H), 5.23–5.09 (m, 3H), 4.73 (d, 2H, $J=5.7$ Hz), 4.60 (s, 1H), 3.21–3.14 (m, 2H), 1.43 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 190.4, 160.8, 155.0, 137.6, 131.2, 119.2, 114.8, 79.3, 65.9, 49.5, 44.3, 28.2; EIMS (m/z , relative intensity): 323 (1), 267 (23), 250 (8), 154 (9), 136 (10), 100 (25), 57 (100), 41 (49), 29 (7). HRMS (EI) calcd for $C_{15}H_{21}N_3O_5$ 323.1481, found 323.1485. $[\alpha]_D^{20} -36.4$ (c 1.4, $CHCl_3$).

3.1.3. (*R*)-3-Allyl 1-*tert*-butyl 2-oxo-5-vinylpyrrolidine-1,3-dicarboxylate (10**).** A solution of **9** (920 mg, 2.85 mmol) in benzene (200 mL)

in a Pyrex tube was irradiated with a 500 W high-pressure Hg lamp with a water-cooled tube inserted into the solvent. The reaction temperature was kept at about 35 °C. The reaction was complete in about 3 h (monitored by IR and TLC). The solution was concentrated under reduced pressure to give the crude product, which was purified by flash chromatography (petroleum ether/ethyl acetate 8:1) to give the diastereomeric mixture of the corresponding 3-allyloxycarbonyl-2-oxo pyrrolidines **10** (504 mg, yield 60%) as a yellowy oil. The diastereomeric mixture could not be separated by column chromatography. IR (film) 2977, 1786, 1731, 1368, 1298, 1251, 1150, 970, 925 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 6.00–5.79 (m, 2H), 5.42–5.17 (m, 4H), 4.75–4.51 (m, 3H), 3.67–3.53 (m, 1H), 2.70–2.66 (m, 1H), 2.26–2.03 (m, 1H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 168.5, 168.2, 149.2, 137.5, 136.0, 131.3, 131.2, 118.9, 118.8, 116.5, 115.8, 83.4, 66.4, 66.3, 59.0, 57.6, 49.0, 48.3, 28.2, 27.8; EIMS (*m/z*, relative intensity): 295 (3), 280 (5), 239 (40), 195 (20), 154 (100), 136 (95), 110 (98), 67 (46), 57 (52), 41 (66). HRMS (EI) calcd for C₁₅H₂₁NO₅ 295.1420, found 295.1422.

3.1.4. (R)-tert-Butyl 2-oxo-5-vinylpyrrolidine-1-carboxylate (11) Compound **10** (183 mg, 0.62 mmol) was dissolved in THF (10 mL), and then morpholine (81 mg, 0.93 mmol, 1.5 equiv) and Pd(PPh₃)₄ (36 mg, 0.031 mmol, 5 mol%) were added in room temperature. When the reaction was complete as monitored by TLC, the solution was concentrated under reduced pressure and purified by flash column chromatography (petroleum ether/ethyl acetate 5:1) to give the pyrrolidine derivative **11** (115 mg, yield 88%) as a yellow oil. IR (film) 2981, 1782, 1750, 1717, 1367, 1305, 1255, 1153, 1020, 850 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 5.91–5.80 (m, 1H), 5.20–5.15 (m, 2H), 4.67–4.62 (m, 1H), 2.64–2.52 (m, 1H), 2.47–2.37 (m, 1H), 2.30–2.17 (m, 1H), 1.86–1.77 (m, 1H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 149.5, 136.4, 115.0, 82.6, 59.4, 30.8, 27.7, 24.0; [α]_D²⁰ +27.7 (c 0.95, CHCl₃).

3.1.5. (R)-2-Oxo-5-vinylpyrrolidine (12)¹⁹ TFA (684 mg, 6 mmol, 5 equiv) was added to a solution of **11** (252 mg, 1.2 mmol) in CH₂Cl₂ (10 mL) at 0 °C and then the reaction was allowed to continue in room temperature overnight. When being completed as monitored by TLC, the reaction was neutralized by saturated NaHCO₃ to pH ≈ 7. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 × 15 mL). The organic layers were then combined and dried over Na₂SO₄. The solution was concentrated under reduced pressure and purified by flash column chromatography (petroleum ether/ethyl acetate 1:1) to give the title compound **12** (131 mg) in nearly quantitative yield as a yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 7.20 (s, 1H), 5.81 (ddd, *J* = 6.7, 10.1, 16.9 Hz, 1H), 5.26–5.10 (m, 2H), 4.23–4.17 (m, 1H), 2.45–2.27 (m, 3H), 1.90–1.78 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 178.8, 138.4, 115.4, 56.6, 29.8, 27.7; [α]_D²⁰ –39.2 (c 1, CHCl₃).

3.1.6. (R)-1-Substituted-5-vinylpyrrolidin-2-ones 13, 14, and 15. The title compounds were obtained from **12** according to literature procedure.²⁰

3.1.7. (R)-1-Allyl-2-oxo-5-vinylpyrrolidine (13) IR (film) 2980, 1687, 1643, 1406, 1278, 1253, 1189, 1128, 992, 923, 844, 726 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 5.76–5.59 (m, 2H), 5.24–5.09 (m, 4H), 4.29 (ddt, *J* = 15.3, 4.8, 1.5 Hz, 1H), 4.05 (dt, *J* = 8.1, 5.4 Hz, 1H), 3.41 (dq, *J* = 7.5, 1.2 Hz, 1H), 2.52–2.32 (m, 2H), 2.30–2.18 (m, 1H), 1.83–1.72 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 174.6, 137.4, 132.3, 117.9, 117.6, 60.6, 42.8, 29.8, 25.2; EIMS (*m/z*, relative intensity): 151 (37), 136 (31), 124 (55), 96 (19), 84 (11), 67 (41), 54 (28), 41 (100), 39 (60), 27 (35); HRMS (ESI) calcd for C₉H₁₃NONa(M+Na) 174.0889, found 174.0887. [α]_D²⁰ –165.1 (c 1.3, CHCl₃).

3.1.8. (R)-1-(But-3-enyl)-2-oxo-5-vinylpyrrolidine (14)²¹ IR (film) 2974, 1687, 1415, 1256, 993, 920 cm⁻¹; ¹H NMR (300 MHz, CDCl₃)

δ 5.82–5.61 (m, 2H), 5.30–5.01 (m, 4H), 4.09–4.02 (m, 1H), 3.71–3.41 (m, 1H), 2.99–2.90 (m, 1H), 2.47–2.33 (m, 2H), 2.30–2.15 (m, 3H), 1.88–1.56 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 174.8, 137.7, 135.2, 117.7, 116.6, 61.2, 39.7, 31.7, 30.0, 25.4; [α]_D²⁰ –58.2 (c 0.85, CHCl₃).

3.1.9. (R)-1-(Pent-4-enyl)-2-oxo-5-vinylpyrrolidine (15)²¹ ¹H NMR (300 MHz, CDCl₃) δ 5.86–5.74 (m, 1H), 5.72–5.60 (m, 1H), 5.27–5.19 (m, 2H), 5.05–4.94 (m, 2H), 4.08–4.00 (m, 1H), 3.59–3.49 (m, 1H), 2.95–2.86 (m, 1H), 2.48–2.34 (m, 2H), 2.30–2.16 (m, 1H), 2.036 (q, *J* = 7.5 Hz, 2H), 1.80–1.69 (m, 1H), 1.67–1.46 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 174.8, 137.8, 137.6, 117.7, 114.8, 61.3, 40.1, 30.9, 30.0, 26.3, 25.4; [α]_D²⁰ –62.6 (c 0.95, CHCl₃).

3.2. General procedure for the RCM reaction

Compound **13**, **14** or **15** (0.08 mmol) was dissolved in dry CH₂Cl₂ (100 mL) under nitrogen atmosphere. Second generation Grubbs catalyst (24 mg, 10 mol%) was added. The resulting mixture was heated at reflux temperature (monitored by TLC). After completion of the reaction, the solvent was then evaporated, and the residual oil was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate 5:1) to give the ring-closing product **16**, **17** or **18** in nearly quantitative yields.

3.2.1. (R)-5,7a-Dihydro-1H-pyrrolizin-3(2H)-one (16)^{21,22} ¹H NMR (300 MHz, CDCl₃) δ 5.92–5.86 (m, 2H), 4.71–4.63 (m, 1H), 4.43–4.36 (m, 1H), 3.71–3.64 (m, 1H), 2.79–2.67 (m, 1H), 2.46–2.30 (m, 2H), 1.89–1.75 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 177.9, 130.5, 128.1, 67.4, 49.6, 34.0, 29.5; IR (film) 3474, 2917, 1681, 1459, 1391, 1280, 1190, 990, 769 cm⁻¹; EIMS (*m/z*, relative intensity): 123 (50), 122 (17), 94 (6), 80 (8), 67 (100), 55 (52), 39 (52), 32 (13), 27 (32); HRMS (ESI) calcd for C₇H₉NONa(M+Na) 146.0576, found 146.0571. [α]_D²⁰ –19.5 (c 0.5, CHCl₃).

3.2.2. (R)-1,2,5,6-Tetrahydroindolizin-3(8aH)-one (17)^{21,23} ¹H NMR (300 MHz, CDCl₃) δ 5.28–5.67 (m, 2H), 4.24–4.15 (m, 2H), 2.90–2.81 (m, 1H), 2.55–2.39 (m, 2H), 2.30–2.20 (m, 2H), 2.11–2.02 (m, 1H), 1.67–1.53 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 172.9, 128.1, 124.8, 54.8, 36.1, 31.5, 26.2, 24.4; IR (film) 2919, 1685, 1437, 1421, 1363, 1306, 1265, 841 cm⁻¹; [α]_D²⁰ +94.0 (c 0.8, CHCl₃).

3.2.3. (R)-5,6,7,9a-Tetrahydro-1H-pyrrolo[1,2-*a*]azepin-3(2H)-one (18)²¹ ¹H NMR (300 MHz, CDCl₃) δ 5.80–5.72 (m, 1H), 5.49 (ddd, *J* = 1.8, 3.7, 11.4 Hz, 1H), 4.37–4.31 (m, 1H), 4.12–4.03 (m, 1H), 3.05–2.97 (m, 1H), 2.50–1.74 (m, 8H); ¹³C NMR (75 MHz, CDCl₃) δ 174.6, 131.8, 131.4, 58.3, 42.6, 29.9, 27.5, 26.7, 26.2; [α]_D²⁰ –7.9 (c 1.35, CHCl₃).

3.2.4. (5R)-3-Allyl 1-tert-butyl 3-allyl-2-oxo-5-vinylpyrrolidine-1,3-dicarboxylate (20) To a solution of **10** (118 mg, 0.4 mmol) in acetone (9 mL) were successively added K₂CO₃ (66 mg, 0.48 mmol, 1.2 equiv), Bu₄NBr (26 mg, 0.08 mmol, 0.2 equiv), and allyl bromide (145 mg, 1.2 mmol, 3 equiv). The resulting mixture was heated at 60 °C for 3 h (monitored by TLC). After cooled to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate 7:1) to give the title compound as a yellow oil (117 mg, 87%). ¹H NMR (300 MHz, CDCl₃) δ 5.96–5.63 (m, 3H), 5.38–5.31 (m, 6H), 4.66–4.61 (m, 2H), 4.56–4.49 (m, 1H), 2.88–2.51 (m, 2H), 2.39–2.25 (m, 1.5H), 1.80–1.70 (m, 0.5H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 170.8, 170.2, 169.7, 138.3, 137.2, 132.3, 131.9, 131.2, 120.1, 119.9, 118.9, 118.6, 116.3, 115.9, 115.7, 83.5, 83.3, 76.5, 66.3, 66.3, 58.0, 57.3, 56.4, 56.1, 39.4, 38.3, 33.2, 32.6, 27.8; EIMS (*m/z*, relative intensity): 335 (5),

279 (18), 235 (12), 194 (55), 176 (25), 150 (100), 136 (45), 108 (20), 79 (25), 57 (35), 41 (44); HRMS (EI) calcd for $C_{18}H_{25}NO_5$ 335.1733, found 335.1735.

3.2.5. (5*R*)-tert-Butyl 3-allyl-2-oxo-5-vinylpyrrolidine-1-carboxylates (19a and 19b). Compound **20** (117 mg, 0.35 mmol) was dissolved in THF (8 mL), and then morpholine (46 mg, 0.524 mmol, 1.5 equiv) and Pd(PPh₃)₄ (20 mg, 0.0175 mmol, 5 mol%) were added at room temperature. After the reaction was complete, the solution was concentrated under reduced pressure and purified by flash column chromatography (petroleum ether/ethyl acetate 7:1) to give **19a** (42 mg) and **19b** (41 mg), both as a yellow oil. **Compound 19a:** $R_f=0.6$ (petroleum ether/EtOAc 3:1). IR (film) 2954, 2924, 2853, 1783, 1725, 1458, 1368, 1299, 1255, 1154, 916 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃) δ 5.84–5.70 (m, 2H), 5.23–5.06 (m, 4H), 4.45 (dd, $J=9.0$, 6.0 Hz, 1H), 2.69–2.53 (m, 2H), 2.39–2.29 (m, 1H), 2.24–2.14 (m, 1H), 1.57–1.52 (m, 1H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 175.6, 149.9, 138.9, 134.9, 117.2, 115.5, 82.9, 58.6, 42.2, 35.2, 30.2, 27.8; EIMS (m/z , relative intensity): 251 (28), 236 (4), 195 (100), 151 (92), 109 (95), 79 (83), 67 (92), 56 (85), 41 (84); HRMS (EI) calcd for $C_{14}H_{21}NO_3$ 251.1521, found 251.1523. $[\alpha]_D^{20} -17.1$ (c 0.96, CHCl₃). **Compound 19b:** $R_f=0.7$ (petroleum ether/EtOAc 3:1). IR (film) 2954, 2924, 2845, 1783, 1717, 1461, 1299, 1255, 1154, 912 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃) δ 5.91–5.69 (m, 2H), 5.19–5.05 (m, 4H), 4.62–4.57 (m, 1H), 2.72–2.60 (m, 2H), 2.23–2.12 (m, 1H), 2.01–1.86 (m, 2H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 175.0, 149.7, 136.3, 134.8, 117.2, 115.1, 82.7, 57.3, 40.7, 34.2, 30.4, 27.8; EIMS (m/z , relative intensity): 251 (30), 236 (6), 195 (100), 151 (90), 109 (93), 79 (82), 67 (90), 56 (84), 41 (82); HRMS (EI) calcd for $C_{14}H_{21}NO_3$ 251.1521, found 251.1523; $[\alpha]_D^{20} +33.5$ (c 1.1, CHCl₃).

3.2.6. (1*R*,5*R*)-tert-Butyl 7-oxo-6-azabicyclo[3.2.1]oct-3-ene-6-carboxylate ((+)-23)¹⁶. Compound **19a** (20 mg, 0.08 mmol) was dissolved in dry CH₂Cl₂ (40 mL) under nitrogen atmosphere. Second generation Grubbs catalyst (1 mg, 1 mol%) was added. The resulting mixture was heated at reflux temperature for 0.5 h (monitored by TLC). The solvent was then evaporated, and the residual oil was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate 5:1) to give the ring-closing product (+)-**23** (18 mg, quant.) as a pale yellow oil. IR (film) 2978, 2929, 1782, 1751, 1707, 1345, 1309, 1252, 1160, 1138, 911, 784, 676 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃) δ 6.34–6.29 (m, 1H), 5.72–5.66 (m, 1H), 4.36–4.33 (m, 1H), 2.85–2.84 (m, 1H), 2.52–2.36 (m, 2H), 2.31–2.24 (m, 1H), 2.00 (dd, $J=9$, 12 Hz, 1H), 1.52 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 176.3, 149.4, 130.7, 127.8, 82.5, 52.5, 41.5, 31.7, 28.6, 28.0; $[\alpha]_D^{20} = 121.0$ (c 0.92, CHCl₃).

3.2.7. (R)-3-Allyl 1-tert-butyl 3-(but-3-enyl)-2-oxo-5-vinylpyrrolidine-1,3-dicarboxylate (21). The title compound was obtained as a yellow oil (85%), following the method we employed for the preparation of **20**. IR (film) 2982, 1785, 1728, 1303, 1199, 1153, 918 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃) δ 5.96–5.70 (m, 3H), 5.37–5.12 (m, 4H), 5.06–4.95 (m, 2H), 4.66–4.52 (m, 3H), 2.75 (dd, $J=7.8$, 13.5 Hz, 0.4H), 2.47 (dd, $J=2.7$, 13.5 Hz, 0.6H), 2.32–1.96 (m, 3.5H), 1.92–1.78 (m, 1H), 1.72–1.65 (m, 0.5H), 1.50–1.49 (d, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.1, 171.0, 170.3, 169.8, 149.4, 138.3, 137.1, 137.0, 136.9, 131.2, 118.9, 118.6, 116.3, 115.8, 115.8, 115.3, 83.4, 83.2, 76.4, 66.2, 66.2, 58.0, 57.2, 57.1, 56.6, 56.0, 34.6, 34.2, 33.6, 33.5, 28.8, 28.5, 27.8; EIMS (m/z , relative intensity): 293 (12), 276 (4), 249 (16), 239 (46), 208 (8), 195 (57), 57 (86), 41 (100), 28 (21). Anal. Calcd for $C_{19}H_{27}NO_5$: C, 65.31; H, 7.79; N, 4.01. Found: C, 65.19; H, 7.81; N, 4.03.

3.2.8. (5*R*)-tert-Butyl 3-(but-3-enyl)-2-oxo-5-vinylpyrrolidine-1-carboxylates (22a and 22b). Compound **21** (200 mg, 0.57 mmol) was dissolved in THF (8 mL), and then morpholine (75 mg, 0.86 mmol, 1.5 equiv), Pd(PPh₃)₄ (33 mg, 0.0286 mmol, 5 mol%) were added at room temperature. The resulting mixture was stirred

for about 2 h (monitored by TLC). After the reaction was complete, the solution was concentrated under reduced pressure and purified by flash column chromatography (petroleum ether/ethyl acetate 7:1) to give **22a** (61 mg) and **22b** (63 mg) both as a yellow oil. **Compound 22a:** $R_f=0.6$ (petroleum ether/EtOAc 3:1). ¹H NMR (300 MHz, CDCl₃) δ 5.85–5.72 (m, 2H), 5.31–5.13 (m, 3H), 5.07–4.98 (m, 2H), 4.43 (q, $J=7.3$ Hz, 1H), 2.54–2.33 (m, 2H), 2.24–1.97 (m, 3H), 1.50 (s, 9H), 1.47–1.40 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 176.2, 149.9, 138.9, 137.4, 115.5, 115.4, 82.9, 58.7, 41.9, 31.2, 30.3, 27.8; IR (film) 2980, 1782, 1746, 1721, 1367, 1299, 1256, 1152, 914 cm^{-1} ; EIMS (m/z , relative intensity): 209 (17), 192 (4), 165 (10), 155 (56), 111 (28), 84 (34), 67 (25), 57 (100), 49 (53), 41 (50), 29 (28). Anal. Calcd for $C_{15}H_{23}NO_3$: C, 67.90; H, 8.74; N, 5.28. Found: C, 67.81; H, 8.66; N, 5.06. $[\alpha]_D^{20} +0.7$ (c 1.2, CHCl₃). **Compound 22b:** $R_f=0.7$ (petroleum ether/EtOAc 3:1). ¹H NMR (300 MHz, CDCl₃) δ 5.91–5.72 (m, 2H), 5.19–5.13 (m, 2H), 5.07–4.97 (m, 2H), 4.62–4.57 (m, 1H), 2.62–2.51 (m, 1H), 2.21–1.99 (m, 4H), 1.91–1.80 (m, 1H), 1.50(d, 9H), 1.45–1.37 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 175.7, 149.7, 137.5, 136.3, 115.3, 115.1, 82.6, 57.3, 40.4, 31.1, 31.0, 29.2, 27.8; IR (film) 2980, 1782, 1748, 1718, 1306, 1199, 1152, 913 cm^{-1} ; EIMS (m/z , relative intensity): 209 (65), 192 (11), 165 (20), 155 (100), 137 (11), 121 (11), 111 (50), 94 (29), 67 (26), 57 (86), 41 (33), 29 (37); Anal. Calcd for $C_{15}H_{23}NO_3$: C, 67.90; H, 8.74; N, 5.28. Found: C, 67.83; H, 8.72; N, 5.38. $[\alpha]_D^{20} +17.6$ (c 0.4, CHCl₃).

3.2.9. (1*R*,6*R*)-tert-Butyl 8-oxo-7-azabicyclo[4.2.1]non-4-ene-7-carboxylate (24). The title compound was obtained as a pale yellow oil in nearly quantitative yield, following the method we employed for the preparation of (+)-**23**. **Compound 24:** IR (film) 2977, 2934, 1781, 1746, 1713, 1366, 1304, 1273, 1255, 1146, 1011, 840, 781 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃) δ 6.06 (ddd, $J=3.0$, 6.5, 11.0 Hz, 1H), 5.87 (ddd, $J=3.2$, 8.4, 11.3 Hz, 1H), 4.52 (t, $J=7.1$ Hz, 1H), 2.93–2.89 (m, 1H), 2.43–2.16 (m, 4H), 1.86–1.78 (m, 1H), 1.74 (d, $J=12.1$ Hz, 1H), 1.51 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 177.2, 149.7, 133.2, 132.5, 82.6, 56.1, 44.2, 33.2, 32.0, 28.0, 24.7; EIMS (m/z , relative intensity): 237 (7), 181 (36), 164 (24), 137 (39), 121 (13), 109 (12), 93 (36), 79 (28), 57 (100), 41 (45), 29 (19), 27 (12). Anal. Calcd for $C_{13}H_{19}NO_3$: C, 65.80; H, 8.07; N, 5.90. Found: C, 65.83; H, 8.02; N, 5.78. $[\alpha]_D^{20} +6.0$ (c 1.0, CHCl₃).

3.2.10. (R)-1-(2-Vinylpyrrolidin-1-yl)prop-2-en-1-one ((R)-25)²⁴ LiAlH₄ (40 mg, 1.05 mmol, 1.2 equiv) was added to a stirred solution of **12** (98 mg, 0.88 mmol) in THF (5 mL) at 0 °C under a nitrogen atmosphere. After 5 min the reaction mixture was allowed to reflux for about 4 h (monitored by TLC). After cooling to room temperature, the reaction mixture was quenched with saturated aqueous potassium sodium tartrate tetrahydrate and stirred for another 2 h. Then the mixture was extracted with ethyl acetate (10 mL×3). The combined organic layers were dried (Na₂SO₄) and evaporated in vacuo. The resulting residue was used in next step without further purification. To this residue were added 2 mL EtOAc, 2 mL water, and K₂CO₃ (242 mg, 1.76 mmol, 2 equiv) and then cooled to 0 °C, and then acryloyl chloride (119 mg, 1.32 mmol, 1.5 equiv) was added dropwise to this mixture. This acylation reaction proceeded very fast. After about 5 min the reaction mixture was extracted with ethyl acetate (5 mL×3) and combined organic layers were dried over Na₂SO₄. Concentration in vacuo followed by flash chromatography on a column of silica gel (petroleum ether/EtOAc 2:1), afforded the desired product **25** (80 mg, 60% yield) as a yellow oil. ¹H NMR (200 MHz, CDCl₃) δ 6.57–6.26 (m, 2H), 5.90–5.70 (m, 1H), 5.67–5.58 (m, 1H), 5.20–5.03 (m, 2H), 4.51–4.44 (m, 1H), 3.71–3.50 (m, 2H), 2.23–1.71 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ 165.0, 138.1, 136.9, 128.8, 128.6, 127.6, 127.1, 115.2, 114.1, 59.2, 58.5, 46.7, 46.1, 32.3, 30.2, 23.5, 21.4; $[\alpha]_D^{20} +23.2$ (c 1.13, CHCl₃).

3.2.11. (R)-Pyrrolam A (26)¹⁷. Second generation Grubbs catalyst (24 mg, 10 mol%) was added to a solution of **25** (42 mg, 0.28 mmol)

in dry toluene 100 mL under nitrogen atmosphere. The resulting mixture was heated at 80 °C for 12 h (monitored by TLC). The solvent was then evaporated, and the residual oil was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate 1:1) to give the ring-closing product **26** (23 mg, 68% yield) as a white solid. ¹H NMR (200 MHz, CDCl₃) 7.20 (dd, *J*=1.7, 5.8 Hz, 1H), 6.04 (dd, *J*=1.5, 5.7 Hz, 1H), 4.30–4.22 (m, 1H), 3.55–3.41 (m, 1H), 3.33–3.20 (m, 1H), 2.37–2.24 (m, 2H), 2.20–2.04 (m, 1H), 1.23–0.96 (m, 1H); ¹³C NMR (50 MHz, CDCl₃) δ 175.6, 148.7, 128.4, 67.7, 41.8, 29.8, 28.9; [α]_D²⁰ –25.9 (c 0.7 in CHCl₃).

Acknowledgements

The project is generously supported by NSFC (Grant No. 20832002, 20772003, 20821062), the Ministry of Education of China, and National Basic Research Program of China (973 Program, No. 2009CB825300).

Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.tet.2009.12.013.

References and notes

- For some reviews, see: (a) Enders, D.; Thiebes, C. *Pure Appl. Chem.* **2001**, *73*, 573–578; (b) O'hagan, D. *Nat. Prod. Rep.* **2000**, *17*, 435–446; (c) Pinder, A. R. *Nat. Prod. Rep.* **1992**, *9*, 17–23; (d) Massiot, G.; Ddelaude, C. In *Alkaloids*; Brossi, A., Ed.; Academic: New York, NY, 1996; Vol. 27, p 269.
- (a) Felpin, F.-X.; Lebreton, J. *Eur. J. Org. Chem.* **2003**, 3693–3712; (b) O'Hagan, B. *Nat. Prod. Rep.* **2000**, *17*, 435–446; (c) Moreno-Clavijo, E.; Carmona, A. T.; Vera-Ayoso, Y.; Moreno-Vargas, A. J.; Bello, C.; Vogel, P.; Robina, I. *Org. Biomol. Chem.* **2009**, *7*, 1192–1202; (d) Ribes, C.; Falomir, E.; Murga, J.; Carda, M.; Marco, J. A. *Org. Biomol. Chem.* **2009**, *7*, 1355–1360; (e) Cheng, X.-C.; Wang, Q.; Fang, H.; Tang, W.; Xu, W.-F. *Eur. J. Med. Chem.* **2008**, *43*, 2130–2139; (f) Reddy, J. S.; Rao, B. V. *J. Org. Chem.* **2007**, *72*, 2224–2227; (g) Zhang, S.; Xu, L.; Miao, L.; Shu, H.; Trudell, M. L. *J. Org. Chem.* **2007**, *72*, 3133–3136; (h) Santarem, M.; Vanucci-Bacqué, C.; Lhomme, G. *J. Org. Chem.* **2008**, *73*, 6466–6469; (i) Ribes, C.; Falomir, E.; Carda, M.; Marco, J. A. *J. Org. Chem.* **2008**, *73*, 7779–7782; (j) Dougherty, A. M.; McDonald, F. E.; Liotta, D. C.; Moody, S. J.; Pallas, D. C.; Pack, C. D.; Merrill, A. H. *Org. Lett.* **2006**, *8*, 649–652.
- Michael, J. P. *Nat. Prod. Rep.* **2008**, *25*, 139–165.
- Kam, T. S.; Sim, K. M. *Phytochemistry* **1998**, *47*, 145–147.
- (a) Asano, N. *Glycosidase-Inhibiting Alkaloids: Isolation, Structure, and Application In Modern Alkaloids*; Fattorusso, E., Tagliatalata-Scafati, O., Eds.; Wiley-VCH: Weinheim, 2008; Chapter 5, pp 111–138; (b) Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. *J. Tetrahedron: Asymmetry* **2000**, *11*, 1645–1680.
- Wilson, R. M.; Danishefsky, S. J. *J. Org. Chem.* **2006**, *71*, 8329–8351.
- Dong, C.; Mo, F.; Wang, J. *J. Org. Chem.* **2008**, *73*, 1971–1974.
- For review: (a) Pandit, U. K.; Overkleeft, H. S.; Borer, B. C.; Bieräugel, H. *Eur. J. Org. Chem.* **1999**, 959–968; For examples: (b) Fuerstner, A.; Korte, A. *Chem. Asian J.* **2008**, *3*, 310–318; (c) Muroli, D.; Mucedda, M.; Saba, A. *Tetrahedron Lett.* **2008**, *49*, 2373–2376; (d) Wakamatsu, H.; Sato, Y.; Fujita, R. o; Mori, M. *Adv. Synth. Catal.* **2007**, *349*, 1231–1246; (e) Sletten, E. M.; Liotta, L. J. *J. Org. Chem.* **2006**, *71*, 1335–1343; (f) Chang, M.-Y.; Hsu, R.-T.; Tseng, T.-W.; Sun, P.-P.; Chang, N.-C. *Tetrahedron* **2004**, *60*, 5545–5550; (g) Ahn, J.-B.; Yun, C.-S.; Kim, K. H.; Ha, D.-C. *J. Org. Chem.* **2000**, *65*, 9249–9251; (h) White, J. D.; Hrnčiar, P. *J. Org. Chem.* **2000**, *65*, 9129–9142; (i) Overkleeft, H. S.; Burggeman, P.; Pandit, U. K. *Tetrahedron Lett.* **1998**, *39*, 3869–3872; (j) Martin, S. F.; Chen, H.-J.; Courtney, A. K.; Liao, Y.; Pätzelt, M.; Ramser, M. N.; Wagman, A. S. *Tetrahedron* **1996**, *52*, 7251–7264; (k) Fürstner, A.; Langemann, K. *Synthesis* **1997**, 792–803.
- Similar strategy for constructing 9-azabicyclo[4.2.1]nonane skeleton has been reported by Martin and co-workers, see: (a) Washburn, D. G.; Heidebrecht, R. W., Jr.; Martin, S. F. *Org. Lett.* **2003**, *5*, 3523–3525; (b) Brenneman, J. B.; Martin, S. F. *Org. Lett.* **2004**, *6*, 1329–1331; (c) Brenneman, J. B.; Machauer, R.; Martin, S. F. *Tetrahedron* **2004**, *60*, 7301–7314.
- CCDC-746178 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via http://www.ccdc.cam.ac.uk/data_request/cif.
- For reviews, see: (a) Ellman, J. A.; Owens, T. D.; Tang, T. P. *Acc. Chem. Res.* **2002**, *35*, 984–995; (b) Zhou, P.; Chen, B. C.; Davis, F. A. *Tetrahedron* **2004**, *60*, 8003–8030; (c) Morton, D.; Stockman, R. A. *Tetrahedron* **2006**, *62*, 8869–8905; (d) Davis, F. A. *J. Org. Chem.* **2006**, *71*, 8993–9003.
- (a) Davis, F. A.; Reddy, R. E.; Szweczyk, J. M. *J. Org. Chem.* **1995**, *60*, 7037–7039; (b) Davis, F. A.; Yang, B. *J. Am. Chem. Soc.* **2005**, *127*, 8398–8407; (c) Davis, F. A.; Ramachandar, T.; Chai, J.; Skucas, E. *Tetrahedron Lett.* **2006**, *47*, 2743–2746; (d) Davis, F. A.; Zhang, Y.; Li, D. *Tetrahedron Lett.* **2007**, *48*, 7838–7840; (e) Davis, F. A.; Ramachandar, T. *Tetrahedron Lett.* **2008**, *49*, 870–872.
- (a) Wang, J.; Hou, Y. *J. Chem. Soc., Perkin Trans. 1* **1998**, 1919–1924; (b) Wang, J.; Hou, Y.; Wu, P.; Qu, Z.; Chan, A. S. C. *Tetrahedron: Asymmetry* **1999**, *10*, 4553–4561; (c) Lee, D. J.; Kim, K.; Park, Y. *J. Org. Lett.* **2002**, *4*, 873–876.
- Pd catalyzed deallyloxycarbonylation examples: (a) Georgiades, S. N.; Clardy, J. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3117–3121; (b) Tsuji, J.; Nisar, M.; Shimizu, I. *J. Org. Chem.* **1985**, *50*, 3416–3417; (c) Jeffrey, P. D.; McCombie, S. W. *J. Org. Chem.* **1982**, *47*, 587–590; (d) Tanaka, S.; Saburi, H.; Murase, T.; Yoshimura, M.; Kitamura, M. *J. Org. Chem.* **2006**, *71*, 4682–4684.
- For examples: (a) Khatri, N. A.; Schmitthenner, H. F.; Shringarpure, J.; Weinreb, S. M. *J. Am. Chem. Soc.* **1981**, *103*, 6387–6393; (b) Weinreb, S. M.; Khatri, N. A.; Shringarpure, J. *J. Am. Chem. Soc.* **1979**, *101*, 5073–5074.
- Yeung, Y.-Y.; Hong, S.; Corey, E. J. *J. Am. Chem. Soc.* **2006**, *128*, 6310–6311.
- (a) Grote, R.; Zeeck, A.; Stümpfel, J.; Zähler, H. *Liebigs Ann. Chem.* **1990**, 525–530. For the recent examples of syntheses: (b) Watson, R. T.; Gore, V. K.; Chandupatla, K. R.; Dieter, R. K.; Snyder, J. P. *J. Org. Chem.* **2004**, *69*, 6105–6114; (c) Majik, M. S.; Shet, J.; Tilve, S. G.; Parameswaran, P. S. *Synthesis* **2007**, *5*, 663–665; (d) Schobert, R.; Wicklein, A. *Synthesis* **2007**, *10*, 1499–1502.
- Preparation of **6**: Davis, F. A.; Zhang, Y.; Andemichael, Y.; Fang, T.; Fanelli, D. L.; Zhang, H. *J. Org. Chem.* **1999**, *64*, 1403–1406.
- (a) Wei, Z. Y.; Knaus, E. E. *Org. Prep. Proced. Int.* **1993**, *25*, 255–258; (b) Silverman, R. B.; Bichler, K. A.; Leon, A. J. *J. Am. Chem. Soc.* **1996**, *118*, 1241–1252.
- Arjona, O.; Csáky, A. G.; Medel, R.; Plumet, J. *J. Org. Chem.* **2002**, *67*, 1380–1383.
- (a) Sattely, E. S.; Cortez, G. A.; Moebius, D. C.; Schrock, R. R.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2005**, *127*, 8526–8533; (b) Martin, S. F.; Chen, H. J.; Courtney, A. K.; Liao, Y.; Pätzelt, M.; Ramser, M. N.; Wagman, A. S. *Tetrahedron* **1996**, *52*, 7251–7264; (c) Martin, S. F.; Liao, Y.; Chen, H. J.; Ramser, M. N. *Tetrahedron Lett.* **1994**, *35*, 6005–6008.
- Andersson, P. G.; Baekvall, J. E. *J. Am. Chem. Soc.* **1992**, *114*, 8696–8698.
- Flann, C.; Malone, T. C.; Overman, L. E. *J. Am. Chem. Soc.* **1987**, *109*, 6097–6107.
- (a) Arisawa, M.; Takahashi, M.; Takezawa, E.; Yamaguchi, T. Y.; Torisawa, Nishida, A.; Nakagawa, M. *Chem. Pharm. Bull.* **2000**, *48*, 1593–1596; (b) Arisawa, M.; Takezawa, E.; Nishida, A.; Mori, M.; Nakagawa, M. *Synlett* **1997**, 1179–1180.